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ABSTRACT
Correct myelination is crucial for the function of the peripheral
nervous system. Both positive and negative regulators within the
axon and Schwann cell function to ensure the correct onset
and progression of myelination during both development and
following peripheral nerve injury and repair. The Sox2 transcription
factor is well known for its roles in the development andmaintenance
of progenitor and stem cell populations, but has also been proposed
in vitro as a negative regulator of myelination in Schwann cells. We
wished to test fully whether Sox2 regulates myelination in vivo
and show here that, in mice, sustained Sox2 expression in vivo
blocks myelination in the peripheral nerves and maintains
Schwann cells in a proliferative non-differentiated state, which is
also associated with increased inflammation within the nerve. The
plasticity of Schwann cells allows them to re-myelinate regenerated
axons following injury and we show that re-myelination is also
blocked by Sox2 expression in Schwann cells. These findings
identify Sox2 as a physiological regulator of Schwann cell
myelination in vivo and its potential to play a role in disorders of
myelination in the peripheral nervous system.
KEY WORDS: Schwann cell, Myelination, Sox2, Repair, Peripheral
nervous system, Mouse
INTRODUCTION
Schwann cells (SC) are themyelinating glia of the peripheral nervous
system (PNS); they myelinate large diameter axons and provide
trophic support for bothmotor and sensory axons. The transcriptional
programmes driving both myelination and the dedifferentiation of
SCs following injury have been partially characterised and many
positive regulators, such as Krox20 (Egr2), Oct6 (SCIP or Tst1),
Sox10 and Nfatc4, have been identified by both in vitro and in vivo
analysis. However, there is still little data on the potential negative
regulators of myelination in vivo that play roles in both the correctly
timed onset of myelination and possibly in the pathology of
demyelinating neuropathies of the PNS (Topilko et al., 1994;
Svaren andMeijer, 2008; Jaegle et al., 1996; Finzsch et al., 2010;Kao
et al., 2009; Jessen and Mirsky, 2008).
Although the transcription factors Pax3, Jun (cJun) and Sox2,
activation of the Notch pathway, and signalling through Erk1/2 and
p38 mitogen activated protein (MAP) kinases have been shown to
inhibit myelination of SCs in vitro, there is only direct genetic
evidence available for Notch signalling, Erk1/2 and p38 activation
regulating these processes in vivo (Yang et al., 2012; Le et al., 2005;
Parkinson et al., 2008; Harrisingh et al., 2004; Woodhoo et al.,
2009; Doddrell et al., 2012; Jessen and Mirsky, 2008; Napoli et al.,
2012; Ishii et al., 2016, 2013; Roberts et al., 2016).
The high mobility group (HMG) domain transcription factor Sox2
has been shown in vitro, using SC/dorsal root ganglion (SC/DRG)
co-cultures and adenoviral overexpression of Sox2 in SCs, to inhibit
the induction of Krox20 and myelination of axons (Le et al., 2005),
but a demonstration of the potential inhibitory role of Sox2 in vivo
within the intact peripheral nerve has not yet been provided. In order
to test the role of Sox2 in vivo, we have made use of a conditional
Sox2IRESGFP allele (Lu et al., 2010), which is activated in a cell-
specific manner by crossing with the SC-specific P0-CRE line, and
have tested the effects of ongoing Sox2 expression upon PNS
myelination and repair. These experiments show, for the first time,
that in vivo Sox2 will suppress PNS myelination and re-myelination
following injury. In addition, persistent Sox2 expression in the adult
nerve is sufficient to induce SC proliferation and an ongoing
inflammatory state within the intact peripheral nerve.
RESULTS
Sox2 blocks Krox20-driven expression of myelin-associated
proteins
The analysis of mice with a hypomorphic allele of Krox20/Egr2
(Egr2Lo/Lo) showed PNS hypomyelination and continued postnatal
expression of the Sox2 transcription factor in SCs (Le et al., 2005).
This study also showed that high levels of Sox2 in SCs blocked the
in vitro induction of Krox20 by cAMP and myelination in SC/DRG
co-cultures. Previous analysis of inhibitors of myelination, e.g. Jun,
have shown that Jun can both inhibit the induction of Krox20 in SCs
as well as prevent the ability of exogenously expressed Krox20 to
induce myelinating SC markers. In this way, Jun acts as an inhibitor
of myelination both upstream and downstream of Krox20 function
(Parkinson et al., 2004). While Sox2 has been shown to block
Krox20 induction in SCs by cAMP (Le et al., 2005), we tested
whether maintained Sox2 can also inhibit the action of the pro-
myelinating transcription factor Krox20 in inducing myelinating SC
markers (Parkinson et al., 2004). In adenoviral co-infection
experiments, as expected, Krox20 induced both the expression of
myelin protein zero (P0; Mpz) and the myelinating cell marker
periaxin in SCs (Parkinson et al., 2003, 2004). Co-expression of
Sox2 with Krox20 in SCs showed that Sox2 strongly antagonisedReceived 24 February 2017; Accepted 13 July 2017
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Krox20-induced expression of both P0 and periaxin (Fig. 1A-I),
confirming, in vitro, that maintained Sox2 expression blocks the
myelination programme both upstream and downstream of Krox20
induction in SCs.
Sox2 expression inhibits myelination in vivo
We next tested whether Sox2 can act as an inhibitor of myelination
in vivo within the intact nerve. A conditional overexpressing allele
for Sox2 (Sox2IRESGFP), inserted into the Rosa26 locus, has been
described that, upon CRE-mediated recombination, expresses both
Sox2 and enhanced green fluorescent protein (GFP) (Lu et al.,
2010). In order to drive SC-specific expression of Sox2, we used the
mP0TOTA-CRE (P0-CRE) line (Feltri et al., 1999) to remove the
floxed ‘stop-cassette’ sequence and allow cell-specific expression
of Sox2 and GFP in SCs. We have characterised nerves from
transgenic CRE+ mice that have either one (Sox2HetOE) or both
(Sox2HomoOE) recombinant Rosa26-Sox2IRESGFP alleles and the
effects of Sox2 expression upon PNS myelination and repair.
We first analysed sciatic nerves of mice carrying one copy of the
Sox2IRESGFP transgene. Rosa26 wild-type/Sox2IRESGFP/CRE+
mice (Sox2HetOE) showed both Sox2 and GFP expression in SCs
of the nerve. Sox2 expression in control and Sox2HetOE nerves
was confirmed by western blot and immunolabelling (Fig. 2I,J;
Fig. S1A-D). These nerves and controls were analysed at postnatal
day (P) 7 and P21 by transmission electron microscopy (TEM)
(Fig. 2A-D). Although there is no apparent defect at this stage in
axonal sorting (SCs appear to make a normal 1:1 relationship with the
axons), there is a substantial reduction in myelin thickness at P7
(Fig. 2B,E) and at P21 (Fig. 2D,G) resulting in an increased average
G-ratio (0.71±0.003) for Sox2HetOE compared with control (0.68±
0.002) at P21. Western blotting of sciatic nerve from control and
Sox2HetOE at both P3 and P7 showed decreased Krox20 as well as
reduced myelin proteins P0 and myelin basic protein (MBP, Fig. 2I).
We also observed significant increases in the numbers of
unmyelinated axons at both P7 and P21 in Sox2HetOE nerves
compared with controls (Fig. 2F,H).
Analysing Sox2HetOE animals at later timepoints, we observed
that the myelination in the PNS appeared to return to normal. At P60
there was no significant difference in G-ratio compared with control
animals (0.65±0.02 for Sox2HetOE compared with 0.66±0.02 for
controls), nerve morphology of Sox2HetOE nerves was completely
normal at P60 (Fig. 3L; Fig. S1J-L) and electrophysiology of
Sox2HetOE nerves showed no changes in nerve conduction velocity
at P90 compared with controls (Fig. S1I). We analysed expression
of the Sox2IRESGFP transgene in these Sox2HetOE animals and
found that the expression of both Sox2 and GFP was high at P7 but
declined from P21 onwards and was undetectable at later time
points, either by western blot or immunocytochemistry; this
decrease in GFP expression was associated with onset of
myelination in the Sox2HetOE nerves (Fig. 2J; Fig. S1A-H). We
were unable to discern why expression levels of Sox2 and GFP
decline in these Sox2HetOE mice, but it does show that loss of Sox2
overexpression in a hypomyelinated nerve from P21 onwards will
allow myelination to proceed such that it appears normal by P60 in
the mouse PNS.
Next, we performed crosses to generate animals carrying two
copies of the Sox2IRESGFP transgene and examined whether in
this case Sox2 expression persisted in the nerve in CRE+
(Sox2HomoOE) animals and effects of such expression.
Sox2HomoOE animals showed a similar hypomyelinating
phenotype with ongoing Sox2 expression at P7, P14 and P21 time
points in CRE+ animals and Sox2 continued to be expressed up to
P60, as measured by either immunolabelling or western blot
(Fig. 3A-H,K and data not shown).
P60 adult Sox2HomoOE animals were smaller in size compared
with controls and showed a typical hindlimb clasping when lifted by
Fig. 1. Sox2 antagonises Krox20-induced myelin
protein expression in vitro. (A-H) Immunofluorescence of
rat SCs infected with GFP/Krox20- (A,B,E,F) or Sox2/
Krox20- (C,D,G,H) expressing adenovirus, showing
inhibition of Krox20-driven periaxin (C,D) and P0
expression (G,H) by Sox2. Hoechst stain (Ho) is used to
reveal SC nuclei. Scale bars: 20 µm. (I) Percentage of
periaxin and P0-positive cells in GFP/K20 and Sox2/K20
adenoviral-infected SCs. Two-sided two-sample Student’s
t-test; data from n=3 biological replicate experiments;
***P<0.005.
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the tail (Fig. 3N-P), indicating a possible reduction of PNS
myelination. TEM analysis of P60 Sox2HomoOE nerves showed
hypomyelination within the adult nerve (Fig. 3I,J), showing that
ongoing Sox2 expression will inhibit myelination even at this later
time point in vivo. Immunocytochemistry and western blotting of
Sox2HomoOE nerves at both P7 and P60 showed reduced levels of
Krox20 and of the myelin proteins P0 and MBP (Fig. 3K; Fig. S2A-
F,I). Levels of the Sox10 transcription factor protein, a key driver of
myelination (Finzsch et al., 2010; Fröb et al., 2012), were
unchanged at P7, but actually increased in Sox2HomoOE nerves at
P60 (Fig. S2G), presumably due to increased numbers of SCs within
the nerve (see below and Fig. 7). Corresponding to the reduction in
myelin protein expression, a significant increase in the G-ratio and
numbers of unmyelinated axons was observed in Sox2HomoOE
nerves at P60 compared with control and Sox2HetOE animals
(Fig. 3L,M).
More-detailed examination of P7 and P60 Sox2HomoOE nerves
showed a number of additional effects of Sox2 expression upon
nerve morphology. At P7, although SCs are making a 1:1
relationship with axons, there is stalling of the ensheathment
(Fig. 4A,B). In addition, at this age, where myelination is observed,
we see an apparent lack of compaction in the outer myelin
membrane layers of the SCs (Fig. 4D,E). At P60, semi-thin and
cryostat sections of Sox2HomoOE nerves show reduced myelination,
but also evidence of both axonal loss and ongoing myelin
breakdown (Fig. 4F,G,Q-T). Additionally, at P60 we saw highly
disorganised Remak bundles within the Sox2HomoOE nerves, with
groups of small diameter axons not separated by SC cytoplasm, in
contrast to control nerves, and observed SCs extending abnormal
processes and engulfing collagen fibres (Fig. 4H-L). An
examination of basal lamina structure in P60 Sox2HomoOE nerves
with α6 integrin and laminin α2 staining showed an abnormal and
diffuse staining pattern in Sox2HomoOE nerves when compared with
controls (Fig. 4M-P). Similar behaviour was observed using in vitro
SC/DRG myelinating co-cultures with Sox2-overexpressing SCs;
21 days after ascorbic acid addition to trigger myelination, Sox2-
overexpressing SCs did not associate correctly with axons,
produced many cellular processes and very little myelin when
compared with controls (Fig. S3).
Sox2 overexpression reduces nerve conduction velocity
(NCV), motor function and sensory function
Following on from the molecular characterisation of nerves
overexpressing Sox2, we next compared the NCV in control and
Sox2HetOE animals. Analysis of compound action potentials
revealed that Sox2HetOE nerves have significantly decreased
NCVs compared with control nerves at P21 (Fig. 5A; see
Fig. S4C for examples of original electrophysiological
recordings), although this had corrected by P90 (Fig. S1I),
consistent with the normal myelination at this timepoint in these
animals (Fig. S1J-L). Next, motor functional analysis was tested
using a rotarod with an increasing speed by recording the latency
to fall (Saporta et al., 2012; Wrabetz et al., 2006). A significantly
reduced latency was observed in Sox2HomoOE mice at both 6 weeks
and 8 weeks of age. Although not significant, a slight reduction in
latency was observed in Sox2HetOE mice at 6 weeks and 8 weeks of
age (Fig. 5B,C).
Further analysis of sensory function was carried out using toe
pinch (pressure) and Von Frey filament (light touch) testing.
At 6 weeks, toe pinch testing showed a reduction in the ability of
Sox2HomoOE mice to response to pressure stimuli, compared with
control and Sox2HetOE mice (Fig. S4A). In testing using Von Frey
filaments, we found that Sox2HomoOE mice also had a significantly
decreased ability to respond to light touch stimuli compared with
control mice (Fig. S4B).
Fig. 2. Inhibition of myelination in Sox2-overexpressing mice in vivo.
(A-D) TEMof sciatic nerves from control P7 control (A) and Sox2HetOE (B) mice,
and P21 control (C) and Sox2HetOE (D) mice. Scale bars: 5 µm. (E) The
distribution of myelin thickness in P7 control and Sox2HetOE mouse nerves.
(F) There is a significant increase in the proportion of unmyelinated axons
greater than 1 µm in diameter in the sciatic nerves of P7 Sox2HetOE mice
compared with controls. (G) The distribution of the G-ratio of axons in P21
control and Sox2HetOE nerves. n=3 mice of each genotype. (H) There is a
significant increase in the population of unmyelinated axons greater than 1 µm
in diameter in nerves of P21 Sox2HetOE mice compared with control mice.
(F,H) Two-sided two-sample Student’s t-test; data from n=3 mice of each
genotype; *P< 0.05, **P< 0.01. (I) Western blots showing the reduction in
Krox20, P0 and myelin basic protein (MBP) proteins in P3 and P7 control and
Sox2HetOE nerves. (J) Western blots showing Sox2 and GFP expression in
postnatal control and Sox2HetOE mice.
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Increased levels of immature SC markers N-cadherin and
Jun in adult Sox2HomoOE nerves
N-cadherin is expressed in developing nerve and declines during
myelination with a reciprocal upregulation of E-cadherin, but is
re-expressed following nerve injury (Crawford et al., 2008; Wanner
et al., 2006). Expression of Sox2 in SCs has been shown to drive re-
localisation of N-cadherin, a cell-surface adhesion molecule, and
allow SC clustering in the nerve bridge following injury (Parrinello
et al., 2010). Such clustering is effected by the formation of
adherens junctions through a calcium-dependent homophilic
cadherin-cadherin interaction between SCs (Wanner and Wood,
2002). Immunolabelling of P60 sciatic nerve sections showed a
clear increase in N-cadherin levels in SCs from Sox2HomoOE nerves
compared with controls with an apparent cell membrane localisation
(Fig. 6A-D). Western blotting confirmed an increase in N-cadherin
levels in Sox2HomoOE nerves, as well as increased levels of the Jun
transcription factor, a marker of promyelinating SCs (Parkinson
et al., 2004) (Fig. 6I,J).
β-Catenin is an N-cadherin binding partner and has been
shown to both colocalise at the SC-axon interface to regulate
SC polarity (Lewallen et al., 2011) and to positively regulate
SC proliferation in SC-DRG co-cultures (Gess et al., 2008).
β-Catenin immunolabelling and western blotting showed slightly
raised levels of expression in P60 Sox2HomoOE nerves in vivo
(Fig. 6E-J). Corresponding in vitro experiments with rat SCs
showed that enforced Sox2 expression alters SC morphology
(Fig. S5A,B), localises both N-cadherin and β-catenin to the
SC membrane in a calcium-dependent manner (Fig. S5C-J), and
increased the levels of both proteins (Fig. S5K); interestingly,
expression of a 4-hydroxytamoxifen-regulatable Sox2 (Sox2-
ER™) protein in 3T3 fibroblasts was sufficient to drive
upregulation and membrane localisation of the N-Cadherin
protein after the addition of tamoxifen to this heterologous cell
type (Fig. S6A-E).
SC proliferation is increased by Sox2 expression in vivo
In Sox2HomoOE mice, we saw increased numbers of SCs within the
nerve from P7 onwards (Fig. 7G,H; Fig. S7). To identify whether
Sox2 increased SC proliferation in vivo, we immunolabelled P7 and
P60 nerve sections with Ki67. The number of GFP/Ki67-positive
nuclei was significantly increased in Sox2HomoOE mice at both P7
and P60 (Fig. 7A-F,I,J); however, no significant increase in Ki67
staining or nuclei number was detected at time points as early as P3
(Fig. S7A-E; data not shown).
Fig. 3. Analysis of Sox2 expression andmyelination in
Sox2HomoOE mice carrying two copies of the
Sox2IRESGFP transgene. (A-H) Immunohistochemical
analysis of sciatic nerves demonstrates that control nerves
do not express GFP or Sox2 at P7 (A,B) or P60 (C,D),
whereas Sox2HomoOE nerves have high levels of GFP and
Sox2 expression at both P7 (E,F) and P60 (G,H). Scale
bar: 40 µm. (I,J) TEM images of control (I) and
Sox2HomoOE (J) nerves at P60. Scale bar: 5 µm.
(K) Western blots of control and Sox2HomoOE nerves at P7
and P60 showing reduction in Krox20, P0 and MBP
expression in vivo mediated by Sox2 expression in SCs.
(L,M) G-ratio measurements (L) and numbers of
unmyelinated axons greater than 1 µm in diameter (M) in
control, Sox2HetOE and Sox2HomoOE nerves at P60.
Two-sided two-sample Student’s t-test; data from n=3
mice of each genotype; *P<0.05, ***P<0.005.
(N) Sox2HomoOE mice (black, on right of picture) were
smaller at P60 compared with control animals. (O,P)
Sox2HomoOE animals (P) show hind limb clasping when
lifted by the tail, which is characteristic of peripheral
hypomyelination, when compared with control
littermate (O).
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Increased numbers of macrophages in uninjured Sox2-
overexpressing nerves
Having observed that increased Sox2 expression maintains SCs in
a proliferative non-myelinating state in the adult nerve, and also
some myelin breakdown and axonal degeneration, we next tested
whether this was associated with any increase in macrophages and
other immune cells within the intact nerve. By double labelling for
Iba1 and F4/80, we checked macrophage numbers in P7, P21 and
P60 control and Sox2HomoOE nerves, and found a significant
increase in the numbers of macrophages within these intact
Sox2HomoOE nerves at both P21 and P60 (Fig. 8A-G). An increase,
although not significant, was also found in numbers of CD3-
positive T-cells in intact P60 Sox2HomoOE nerves compared with
controls (Fig. S8).
Sox2 over-expression impairs SC remyelination and
functional recovery following nerve injury
Although Sox2 re-expression has been shown to drive cell sorting in
the nerve bridge following transection injury (Parrinello et al.,
2010), it is not known how maintained Sox2 expression in SCs will
Fig. 4. Morphology of P7 and P60 control and Sox2HomoOE nerves. (A-E) P7 sciatic nerves from control (C) and Sox2HomoOE animals (A,B,D,E). Whereas
control nerve SCs have formed proper myelin (C), in Sox2HomoOE nerves most SCs are stalled in the 1:1 stage (A,B). (D,E) Where Sox2-overexpressing SCs do
form myelin, they often show non-compaction of outer myelin layers (white arrowheads). Scale bars: 500 nm in A,B; 2 µm in C; 200 nm in D,E. (F,G) Semi-thin
sections of P60 control (F) and Sox2HomoOE (G) nerves; arrows in G indicate possible axonal loss and demyelination. Scale bar: 20 µm. (H-L) P60 control (J) and
Sox2HomoOE (H,I,K,L) nerves. At P60, most axons in Sox2HomoOE nerves are amyelinated and surrounded by redundant SC basal lamina (black arrows in H and L),
and several SCs show myelin debris in the cytoplasm (asterisks in I). Remak bundles, which in control nerves show proper SC cytoplasm separating axons (J),
show bundles of axons touching each other (‘b’ in K and L) and aberrant SC processes (white arrow in L), the basal lamina of which forms collagen pockets (white
arrowheads in L). Scale bars: 1 µm in H-L. (M-R) P60 control (M,O,Q) and Sox2HomoOE (N,P,R) nerve sections immunolabelled with α6 integrin (M,N), laminin
α2 (O,P) andmyelin basic protein (MBP)/GFP (Q,R). Scale bars: 5 µm inM-P; 25 µm in Q,R. (S,T) Quantification of myelinated (S) and degenerating (T) fibres per
field in P60 control and Sox2HomoOE nerves. Two-sided two-sample Student’s t-test; data from n=3 mice of each genotype; **P<0.01, ***P<0.005.
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affect nerve repair and regeneration in the distal nerve following a
crush injury. Thus, we next investigated the effect of maintained
Sox2 expression on SC re-myelination up to 21 days post-crush
injury (DPI). As Sox2HomoOE animals show profound
hypomyelination even at P60, we used Sox2HetOE animals for
these experiments. As described above, in Sox2HetOE mice, Sox2
and GFP expression begins to decline at P21 and myelination
corrects to produce normal nerve morphology and G-ratios at P60;
nerve conduction velocity is also unchanged at P90 in these animals
(above and Fig. S1I-L).
As we observe transgene expression of both Sox2 and GFP at
early developmental timepoints in the Sox2HetOE animals, we
hypothesized that following PNS injury the accompanying de-
differentiation of SCs distal to the injury site may be sufficient to
cause re-activation of transgenic Sox2 and GFP expression in the
Sox2HetOE animals, allowing us to study effects of ongoing Sox2
expression in a repairing nerve. This idea proved correct and western
blot and immunolabelling showed higher levels of Sox2 induction
in Sox2HetOE animals compared with controls at 7 DPI and that
Sox2 and GFP expression were maintained at 21 DPI in these
animals compared with controls (Fig. 9A-F,L,M). Using TEM, we
evaluated SC re-myelination by analysing distal nerve sections from
control and Sox2HetOE mice at 21 DPI. Sox2HetOE sciatic nerves
distal to the site of injury were hypomyelinated (Fig. 9G,H), with a
significantly increased average G-ratio of 0.86±0.028 compared
with control nerves, which had an average G-ratio of 0.69±0.028 at
this timepoint (Fig. 9I; see Fig. S9A for G-ratio scatter plot). A
significant increase in the percentage of unmyelinated axons and a
decrease in P0 protein expression were observed in Sox2HetOE
mouse nerves at 21 DPI (Fig. 9J,M).
Although numbers of regenerated axons were apparently
unchanged, as visualised by neurofilament staining, further
analysis of regenerated nerves at 21 DPI did show a significant
increase in the axonal diameter of repaired nerves in Sox2HetOE
animals compared with controls (Fig. S9B), as well as significantly
increased numbers of macrophages still present within the nerve at
this timepoint (Fig. S9C-G). No significant difference in
macrophage numbers was observed between uninjured nerves
from control and Sox2HetOE animals (Fig. S9G).
Having observed that Sox2 overexpression post-injury leads to a
marked reduction in SC re-myelination in Sox2HetOE mice following
injury, we next tested functional recovery of these animals. Tests of
functional recovery using a Static Sciatic Index (SSI) measurement
showed that recovery in Sox2HetOE mice was significantly reduced up
to 21 DPI compared with control mice (Fig. 9K). This experiment
confirmed that, in addition to impairing remyelination, prolonged
Sox2 expression in SCs following injury also attenuates functional
recovery in these animals.
We next quantified re-myelination by analysing myelin protein re-
expression following sciatic nerve injury. Corresponding to TEM
Fig. 5. Nerve conduction velocity and motor function is
reduced in Sox2-overexpressing animals. (A) The nerve
conduction velocities (NCV) of sciatic nerves taken from
control (n=11) and Sox2HetOE (n=13) mice at P21.
(B,C) Reduction in latency to fall using rotarod testing of
control, Sox2HetOE andSox2HomoOEmice at 6 weeks (B) and
8 weeks (C) of age. 6 weeks control, n=7; Sox2HetOE, n=4;
Sox2HomoOE, n=6; 8 weeks control, n=4; Sox2HetOE, n=4;
Sox2HomoOE, n=6. Two-sided two-sample Student’s t-test;
*P<0.05, ***P<0.005.
Fig. 6. Expression and localisation of N-cadherin and β-catenin in P60 Sox2HomoOE nerves. (A-H) Immunolabelling of sciatic nerve sections from P60
control (A,B,E,F) and Sox2HomoOE (C,D,G,H) nerves showing localisation and levels of N-cadherin (Ncad; A-D) and β-catenin (βcat; E-H) in SCs. Sections are
counterstained with Hoechst (Ho) to reveal nuclei. Scale bar: 20 µm. (I) Western blot showing elevated levels of Sox2, N-cadherin and Jun in P60 Sox2HomoOE
nerves. (J) Quantification of western blots in I. Two-sided two-sample Student’s t-test; data from n=3 blots; ***P<0.005.
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analysis (Fig. 9G,H), western blotting confirmed that continued
expression of Sox2 in the SCs of Sox2HetOE nerves following injury
reduced the re-expression of P0 at 21 DPI in the distal nerve (Fig. 9L,M).
Analysis of SC proliferation in Sox2HetOE mice at 21 DPI also
showed an ongoing and significantly increased proliferation in the
nerve even at this timepoint after injury (Fig. 9N), once more
showing the potential for Sox2 to maintain SCs in an
undifferentiated and proliferative state in vivo within the nerve.
DISCUSSION
Within SCs, the onset of myelination is controlled by a network of
transcription factors that cooperate to ensure a timely and appropriate
ensheathment and myelination of axons (Svaren and Meijer, 2008).
Mutations in many of these factors, such as those in the zinc-finger
protein Krox20 (Egr2), cause hypomyelinating neuropathies in both
humans and rodent models (Funalot et al., 2012; Baloh et al., 2009;
Desmazieres et al., 2008; Arthur-Farraj et al., 2006; Warner et al.,
1999, 1998). Although there are a number of positive transcriptional
regulators of myelination in SCs, such as Krox20, Sox10, Nfatc4 and
Oct6, an increasing number of negative regulators of myelination,
such as MAP kinase signalling through p38 and ERK1/2 pathways,
Notch signalling and the transcription factors Pax3 and Jun, have
been shown to block the myelination of SCs (Doddrell et al., 2012;
Harrisingh et al., 2004; Woodhoo et al., 2009; Napoli et al., 2012;
Yang et al., 2012; Parkinson et al., 2004, 2008).
The initial description of Sox2 as an inhibitor of PNS myelination
came from the finding that mice with a hypomorphic Krox20 (Egr2)
allele (Egr2Lo/Lo), and thus reduced Krox20 expression, showed
hypomyelination and increased expression of Sox2 in SCs. Further
experiments, which aimed to determine the function of Sox2 as a
negative regulator of myelination have used a virally mediated
expression system in vitro. These experiments showed that
overexpression of Sox2 in vitro prevents both the induction of
myelinating SC markers such as Krox20 and P0, and enhanced the
proliferation of SCs to the mitogen neuregulin (Le et al., 2005).
Although this gives a good indication of Sox2 function, assays of
myelination in vitro may not fully reflect the situation in vivo
(Lewallen et al., 2011; Golan et al., 2013). Thus, the aim of this study
was to fully characterise the effects of maintained Sox2 expression
upon both myelination and functional repair within the intact nerves
of the PNS in vivo. In addition, this in vivo approach allows us to
measure effects of maintained Sox2 expression in SCs upon immune
cell influx into the nerve, both following injury and in the intact nerve.
Our experiments show a strong inhibitory effect of Sox2 on the
myelination programme of SCs at all timepoints examined. The
expression of myelinating SCmarkers such as Krox20, myelin basic
protein and P0 are all reduced, and morphological analysis shows a
severe hypomyelination of postnatal nerves. Correspondingly, an
analysis of SC-specific Sox2 nulls has shown a slight acceleration
of early postnatal myelination (M.D. and X.P.D., unpublished),
confirming the inhibitory role of Sox2 in controlling developmental
myelination. However, in contrast to experiments with SC-specific
Jun and p38αMAP kinase nulls (Parkinson et al., 2008; Roberts et al.,
2016), we do not observe a function for Sox2 in the downregulation
of myelin proteins following injury. Injury experiments in Sox2-null
nerves showed a similar profile of myelin protein loss compared with
controls (X.P.D., unpublished). Thus, the role of Sox2 appears to be
more important in regulating the onset of myelination both during
development and following injury, rather than in the events of SC
dedifferentiation following axotomy.
An analysis of other potential Sox2 targets showed, both in vitro and
in vivo, that Sox2 decreased mRNA and protein levels of the nectin-
like proteinNecl4 (also known asCadm4) in SCs (Fig. S10). Inhibition
Fig. 7. SC numbers and proliferation are increased in
Sox2-overexpressing nerves. (A-F) Ki67 labelling of
sciatic nerves taken from P7 control (A-C) and
Sox2HomoOE (D-F) mice. Scale bar: 40 µm. Insets in D-F
show higher magnification of Ki67/GFP-positive SCs.
(G,H) There is an increase in the number of SC nuclei in
P7 (G) and P60 (H) Sox2HomoOE sciatic nerves compared
with controls. Numbers given are total nuclei per sciatic
nerve transverse section. (I,J) There is a significant
increase in the number of GFP/Ki67-positive nuclei in
P7 (I) and P60 (J) Sox2HomoOE sciatic nerves. (G-J) Two-
sided two-sample Student’s t-test; data from n=3 mice of
each genotype at each time point; *P<0.05, **P<0.01.
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of Necl4 function in SCs, either by shRNA knockdown or expression
of a dominant-negative form of the protein, prevents normal SC-axon
interaction, Krox20 induction and myelination in vitro (Maurel
et al., 2007; Golan et al., 2013; Spiegel et al., 2007), but loss of
Necl4 in vivo is associated with focal hypermyelination and a
phenotype resembling several CMT subtypes (Golan et al., 2013).
It is therefore unclear at present what role, if any, decreased Necl4
levels may play in the phenotype we observe in our Sox2
overexpressing animals.
Overexpression of the mammalian Lin28 homologue B (Lin28B)
RNA-binding protein and reduction in the levels of the let-7 family
of microRNAs in SCs has been shown to inhibit peripheral nerve
myelination in vivo (Gokbuget et al., 2015). As Sox2 has been
shown to increase Lin28B levels in embryonic stem cells and neural
progenitors (Cimadamore et al., 2013; Marson et al., 2008), we
measured Lin28B protein levels in control and Sox2HomoOE nerves
at P60. We do not detect Lin28B expression in either control or
Sox2HomoOE adult nerve (Fig. S2H); therefore, seemingly
eliminating the Lin28B/let-7 signalling axis as mediating the
Sox2-induced hypomyelination.
It is still unclear why the expression of the Sox2IRESGFP
transgene declines in the Sox2HetOE animals up to P21, as the
construct is inserted into the Rosa26 locus and the construct also
contains a synthetic cytomegalovirus early enhancer/chicken beta
actin (CAG) promoter (Lu et al., 2010); but these issues of silencing
of the transgene expression were not seen in the Sox2HomoOE
animals, allowing us to monitor the effects of Sox2 expression up to
P60 in these animals. Analysis of Sox2HetOE nerves up to P60
allowed us to measure the effects of the removal of Sox2
overexpression in SCs from P21 onwards. In this case, the nerves
continued their myelination and by P60 they appeared normally
myelinated with G-ratios similar to control nerves, once again
underlining a remarkable ability of SCs within the nerve to resume
and complete their myelination programme.
The normal myelination observed in P60 Sox2HetOE nerves and
re-activation of Sox2 expression following injury in these animals
also allowed us to confirm that Sox2 negatively regulates both
developmental myelination and re-myelination following injury, in
contrast to some regulators within SCs that have developmental or
repair-specific functions (Arthur-Farraj et al., 2012; Fontana et al.,
2012; Kim et al., 2000; Jessen and Mirsky, 2016; Mindos
et al., 2017).
Whether negative regulators of myelination play roles in the
pathology of human peripheral neuropathies or mouse models of
these conditions has been recently examined. Increased expression of
the Jun transcription factor in SCs has been observed in patients with
Charcot-Marie-Tooth (CMT) disease or chronic inflammatory
demyelinating polyradiculopathy, and in mouse models of CMT
(Saporta et al., 2012; Hutton et al., 2011; Hantke et al., 2014; Klein
et al., 2014). Although it has been suggested that abnormal
expression of Jun may be involved in the pathology of the
hypomyelination seen (Saporta et al., 2012), recent work using the
C3mousemodel of CMT1A showed that Jun expressionwas actually
protective. Genetic removal of Jun in the C3 mouse, which models
human CMT1A, led to a progressive loss of myelinated sensory
axons and increasing sensory-motor loss (Hantke et al., 2014). Thus,
as opposed to driving the neuropathy in these animals, raised
expression of Jun in SCs is a protective mechanism that ameliorates
Fig. 8. Increased numbers of macrophages in intact
P60 Sox2HomoOE sciatic nerves. (A-F) Double
immunolabelling of P60 control (A-C) and
Sox2HomoOE (D-F) sciatic nerves with F4/80 and Iba1 to
identify macrophages. Scale bar: 40 µm. Insets in D-F
show higher magnification of F4/80/Iba1 double-positive
macrophages. (G) Quantification of macrophage numbers
at P7, P21 and P60; a significant increase in macrophage
numbers is observed in both P21 and P60 Sox2HomoOE
nerves. Two-sided two-sample Student’s t-test; data from
n=3 mice of each genotype at each time point; *P<0.05.
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the disease state. Recent reports have shown that levels of Sox2
mRNA are elevated in mouse models of CMT types 1A and 1B
(D’Antonio et al., 2013; Giambonini-Brugnoli et al., 2005), but any
potential roles for this increased expression are currently unknown.
The finding of increased macrophage numbers within both the
intact Sox2HomoOE nerve at P60 and within the Sox2HetOE nerve
following injury suggests a role for Sox2 in the control of
macrophage entry to the nerve, although it is not clear whether
this is a direct effect, or is due to the lack of myelination or the
apparent ongoing myelin breakdown and axonal loss seen in the
adult P60 Sox2HomoOE nerves (Fig. 4F,G). In conclusion, we have
identified that Sox2 acts as an in vivo inhibitor of the myelinating
phenotype of SCs and have shown new roles for this protein in both
controlling the proliferation of SCs and recruitment of macrophages
to the nerve.
MATERIALS AND METHODS
Reagents
Adenoviruses expressing Krox20/GFP, Sox2/GFP and GFP control have been
previously described (Le et al., 2005; Nagarajan et al., 2001; Parkinson et al.,
2004, 2008). Antibodies against Sox2 were from Novus Biological (NB 110-
37235SS) for western blotting and from Millipore (AB5603) for
immunostaining. Antibodies against myelin basic protein (MBP) (sc-13912),
β2A tubulin (sc-134229) and α6 integrin (F6) were from Santa Cruz
Biotechnology. Antibodies to N-cadherin (610920), β-catenin (610163) and
Jun (610327)were fromBecton-Dickinson. Antibodies toKi67 (Ab15580) and
Sox10 (Ab155279) were from Abcam. Krox20 antibody (PRB-236P) was
from Covance. Anti-laminin α2 antibody (ALX-804-190) was from Enzo.
Antibodies against myelin protein zero (P0), periaxin, Iba1, F4/80 and CD3
were as described previously (Archelos et al., 1993; Gillespie et al., 1994;
Mindos et al., 2017; Napoli et al., 2012). For further details of primary
antibodies used, see the supplementary Materials and Methods. Biotinylated
Fig. 9. Sustained Sox2 expression results in
hypomyelination and reduced functional recovery
following nerve injury. (A-F) Immunolabelling of distal
nerve sections 21 days post-crush injury (DPI) revealed
that nerves from control animals no longer expressed
Sox2 at this time point (A-C), whereas Sox2 (and GFP)
levels remained elevated in the distal sciatic nerves of
injured Sox2HetOE mice (D-F). Scale bar: 40 µm.
(G,H) TEM pictures of distal nerve sections at 21 DPI
revealed that axons in control nerves are
remyelinated (G), whereas few axons are remyelinated in
Sox2HetOE nerves (H). Scale bar: 5 µm. (I) G-ratio
measurements revealed that Sox2HetOE sciatic nerves
were significantly hypomyelinated compared with control
nerves at 21 DPI. (J) There is a significant increase in the
percentage of unmyelinated axons in Sox2HetOE nerves
compared with controls at 21 DPI. Two-sided two-sample
Student’s t-test; data from n=3 mice of each genotype. (K)
Quantification of functional recovery by static sciatic index
(SSI). Control, n=5; Sox2HetOE, n=7. Two-sided two-
sample Student’s t-test. (L) Western blot showing high
levels of Sox2 at 7 and 21 DPI and a reduction in P0
expression in Sox2HetOE mice at 21 DPI. (M)
Quantification of western blots from L. Two-sided two-
sample Student’s t-test; data from n=3 independent blots.
(N) There is significant increase in the number of Ki67-
positive nuclei in distal Sox2HetOE sciatic nerves at 21 DPI.
Two-sided two-sample Student’s t-test; data from n=3
mice of each genotype. *P<0.05, ***P<0.005.
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antibodies, AlexaFluor fluorescently conjugated antibodies and fluorescently
conjugated streptavidin were as previously described (Doddrell et al., 2013).
Transgenic mice and genotyping
Transgenic mouse breeding and experiments were carried out according to
Home Office regulations under the UK Animals (Scientific Procedures) Act
1986. Ethical approval for experiments was granted by Plymouth University
Animal Welfare and Ethical Review Board. To identify effects of Sox2
overexpression in SCs in vivo, we crossed homozygous Rosa26R-
Sox2IRESGFP mice (Lu et al., 2010) with P0-CRE (mP0-TOTACRE)
mice (Feltri et al., 1999). This generated heterozygous Rosa26
Sox2IRESGFP CRE-positive (+) and CRE-negative (−) offspring.
Heterozygous Rosa26 Sox2IRESGFP CRE+ animals were then
backcrossed with homozygous Rosa26 Sox2IRESGFP CRE– mice to
generate heterozygous and homozygous Rosa26R-Sox2IRESGFP CRE–
and CRE+ mice. CRE+ animals carrying one copy of the Rosa26
Sox2IRESGFP transgene are referred to as Sox2HetOE; CRE+ animals
carrying two copies of the Rosa26 Sox2IRESGFP transgene are referred to
as Sox2HomoOE mice. For analysis of both Sox2HetOE and Sox2HomoOE mice,
age and sex-matched CRE− animals of the same Rosa26 Sox2IRESGFP
transgene status are used as controls. For mouse genotyping, genomic DNA
was extracted using the HotSHOT method and analysed as previously
described (Lu et al., 2010; Feltri et al., 1999; Truett et al., 2000).
Nerve injury
For nerve crush injury, the right sciatic nerve was compressed using round end
forceps, as previously described (Dun and Parkinson, 2015). The left sciatic
nerve was left uninjured. Mice were euthanized at the indicated time, and both
uninjured contralateral and injured distal sciatic nerves collected for analysis.
Cell culture and adenoviral/retroviral infection
Rat SCs were prepared from postnatal day 3 rats, as described previously
(Brockes et al., 1979; Parkinson et al., 2001). SCs were infected with GFP/
Krox-20 (GFP/K20) (Parkinson et al., 2004; Nagarajan et al., 2001), control
GFP or GFP/Sox2 adenovirus (Le et al., 2005) or both GFP/Sox2 and GFP/
K20 (Sox2/K20) adenovirus for 24 h in defined medium (DM) (Jessen et al.,
1994) then incubated for a further 24 h in DM before fixing and
immunolabelling. For details of DRG/Schwann cell culture and co-culture,
retroviral/lentiviral constructs and infection, RNA preparation and semi-
quantitative PCR, please see the supplementary Materials and Methods.
Immunocytochemistry, immunohistochemistry and western
blotting
SCs were cultured on poly L-lysine/laminin-coated glass coverslips as
previously described (Jessen et al., 1994). For immunohistochemical
analysis of sections, nerves were fixed in 4% w/v paraformaldehyde and
embedded for cryosectioning. All staining, antibodies, counts and confocal
and fluorescence microscopy were as described previously (Doddrell et al.,
2013; Parkinson et al., 2008, 2003). Anti-MBP (1:100) and anti-Ki67
(1:200) antibodies were diluted in antibody diluting solution with 0.2%
Triton X-100 and incubated overnight at 4°C. For western blotting, nerve
samples were lysed in SDS buffer and electrophoresed on SDS-
polyacrylamide gels (Doddrell et al., 2013; Parkinson et al., 2004, 2008,
2003). β2A tubulin was used as loading control for western blots.
Transmission electron microscopy
Nerves were fixed in 2.5% glutaraldehyde in 0.1M phosphate buffer (pH 7.2),
post-fixed in 1% osmium tetroxide, dehydrated and embedded in resin. Semi-
thin sections were cut using a glass knife and stained with Toluidine Blue.
Ultra-thin sections were cut and stained with uranyl acetate and lead citrate.
Sections were photographed using a JEOL 1200EXor 1400 TEMmicroscope.
For details of electron microscopy analysis of SC/DRG co-cultures and SCs,
see the supplementaryMaterials andMethods. For quantification of the G ratio
in intact and injured nerves, axon diameter and fibre (axon+myelin) diameter
were measured from 200 axons from each animal using Image J, which
allowed for myelin thickness and G-ratio calculation. For quantification of
numbers of myelinated/degenerated fibres per field, average counts were made
from five separate fields from both P60 control and Sox2HomoOE nerves.
Functional testing
Motor capacity in 6- and 8-week-old mice was assessed by rotarod analysis.
Rotarod training and final testing was as previously described (Saporta et al.,
2012; Kuhn et al., 1995). (Rods accelerated from 2 to 30 rotations per minute
over 250 s.)
For nerve conduction velocity (NCV) measurements, sciatic nerves from
P21 or P90 animals were dissected and placed into a perfusion chamber for
30-45 min before measurements were initiated. During this time the sciatic
nerves were incubated at 37°C, and perfused with artificial cerebrospinal fluid
(aCSF) as described previously (Fern et al., 1998; Alix and Fern, 2009). The
distal ends of the sciatic nerves were positioned within an aCSF-filled glass
stimulating electrode and compound action potentials (CAP) were induced
(Alix and Fern, 2009). CAPs were recorded by the second recording aCSF-
filled glass electrode surrounding the proximal end of the sciatic nerve (Fern
et al., 1998) and displayed using Signal software (Cambridge Electronic
Design). NCVs were calculated using two parameters: (1) the length of the
stimulated nerve; and (2) the time difference between the start of the stimulus
artefact to the peak of the CAP. Measurements of sensory function on control
and Sox2HomoOE animals were performed using Von Fray filament and toe
pinch tests; for more details see the supplementary Materials and Methods.
Functional recovery was measured on mice following injury using the
static sciatic index (SSI) measurement. Paw print measurements were taken
using a video camera from each mouse before surgery (0 days) and up to
21 days following injury to calculate the SSI (Baptista et al., 2007).
Statistics
For all experiments, n=3 unless otherwise stated. Graphs display the
arithmetic mean with error bars representing one standard error of the mean.
Statistical analysis was carried out using Student’s t-test and P values are
used to denote significance: *P< 0.05, **P< 0.01, ***P<0.005.
Owing to small sample sizes (n<5 for most comparisons), how well
normality and equal variances fitted the data could not be reliably assessed.
Sample sizewas not predetermined by statistical methods and randomisation
was not applied. For functional testing using the SSI, the evaluation was
made by an individual blinded to the animal genotype. No samples or data
were excluded from the analysis. The n value for each experiment is stated in
the appropriate figure legend.
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Supplementary Figures 
 
Figure S1: Analysis of Sox2 overexpressing nerves at P7, P21 and P60, showing 
post-natal decrease in transgene expression and normalisation of myelination at P60. 
A-D. Immunolabelling of control (A, B) and Sox2HetOE (C, D) sciatic nerves with Sox2 
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antibody showing both GFP and Sox2 expression in the Sox2HetOE nerve sections. 
Scale bar 20m. E, F.  Immunolabelling of P7 control (E) and Sox2HetOE (F) nerves 
showing myelin basic protein (MBP) expression. GFP expressing Schwann cells 
(arrowheads) show no MBP expression, whereas GFP negative cells (arrows) in the 
nerve are MBP positive. Scale bar 5m. G, H. Immunolabelling of P21 control (G) 
and Sox2HetOE (H) nerves showing MBP expression; a single weakly GFP-positive 
cell is indicated (arrowhead). Scale bar 25m. I. Measurement of nerve conduction 
velocity in P90 control and Sox2HetOE nerves. Two sided two sample Student’s t test; 
data from n=3 mice of each genotype. J, K. Transmission electron microscopy (TEM) 
pictures of P60 control (J) and Sox2HetOE (K) nerves. Scale bar 5m. L. Scatter plot 
of G ratio versus axonal diameter for P60 control and Sox2HetOE nerves. 
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Figure S2: Analysis of P60 Sox2HomoOE nerves. A-D. Immunolabelling of P60 control 
(A, B) and Sox2HomoOE (C, D) nerves with Krox20 antibody revealed fewer Krox20 
positive nuclei in Sox2HomoOE sections; sections are counterstained with Hoechst dye 
(Ho) to reveal nuclei. Scale bar 20m. E, F. Immunolabelling with myelin basic 
protein (MBP) antibody on P60 control (E) and Sox2HomoOE (F) nerves. Scale bar 
20m.  G. Western blots of control and Sox2HomoOE P7 and P60 nerves with Sox10 
antibody. H. Western blot of P60 control and Sox2HomoOE nerves with Lin28B 
antibody. Cell extract from the hepatoma cell line HuH-7 was used as a positive 
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control for Lin28B protein expression. I. Quantification of western blots from Figure 
3K for control (Cont.) and Sox2HomoOE nerves. Two sided two sample Student’s t test; 
data from 3 independent blots. 
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Figure S3: TEM images of Schwann cell/DRG neuron co-cultures. A, B. Control 
GFP infected Schwann cells show a normal contact with axons and myelin formation 
at 21 days post-ascorbic acid treatment (Panel B enlargement of Panel A). By 
contrast, Sox2 infected Schwann cells (C, D) do not complete axon ensheathment 
and still protrude cytoplasmic processes in the area at this timepoint (arrowheads in 
panels C and D). M: myelin; Ax: Axon. Scale bars A, C and D: 1m; B: 500nm. 
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Figure S4: Sensory function is reduced in Sox2HomoOE animals. A. Graph showing 
percentage of control (n=7), Sox2HetOE (n=3) and Sox2HomoOE (n=5) animals that 
responded to toe pinch testing at 6 weeks of age. B. Graph showing withdrawal 
threshold (g) for control (n=11), Sox2HetOE (n=5) and Sox2HomoOE (n=5) at 6 weeks of 
age to Von Frey filament sensory testing. Two sided two sample Student’s t test. C. 
Example traces showing electrophysiological measurement of compound action 
potentials in P21 control and Sox2HetOE sciatic nerves. Arrow indicates compound 
action potential peak.  
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Figure S5: Sox2 expression causes cell clustering and relocalisation of N-cadherin 
and -catenin in vitro to cell-cell contacts in Schwann cells. A, B. Scanning electron 
microscopy analysis of control GFP (A) and GFP/Sox2 (B) infected rat Schwann 
cells 48h after adenovirus addition. Sox2 expression causes such strong cell-cell 
adhesion that Schwann cells can form three dimensional clumps that begin to detach 
from the glass coverslip (B’). Scale bar for A, B 25m; B’ 10m. C-J. Sox2 
expression causes a calcium-dependent relocalisation of N-cadherin and -catenin 
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to cell-cell contacts in Schwann cells. Immunocytochemistry of Schwann cells 
infected with GFP/Sox2 expressing adenovirus with antibodies against N-cadherin 
(C-F) and -catenin (G-J). Cells in C, D, G and H were cultured under normal 
calcium concentration whereas cells in panels E, F, I and J were cultured in low 
calcium conditions. Note loss of both cell-cell clustering and membrane localisation 
of N-cadherin and -catenin under low calcium conditions. Scale bar C-J 20m. K. 
Western blot analysis of cell lysates from rat Schwann cells infected with GFP 
control  (GFP) or GFP/Sox2  (Sox2) expressing adenoviruses at 24, 48 and 72 hours 
after infection. Cont. control uninfected rat Schwann cells. Representative blot shown 
from 3 independent experiments. 
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Figure S6: Sox2 expression causes N-cadherin relocalisation in 3T3 fibroblast cells. 
A-D Immunolabelling of 3T3 cells infected with empty control retroviral vector (A, C) 
and retrovirus expressing Sox2ERTM protein (B, D), labelled with antibodies against 
Sox2 (A, B) and N-cadherin (Ncad, C, D). Cells were treated for 48h with 10-6M 4-
hydroxytamoxifen (4-OHT) before fixing. Nuclei are labelled with Hoechst dye (Ho) in 
panels C and D. Scale bar 20m.  E. Western blot showing levels of N-cadherin 
protein in control empty vector (BP2) and Sox2ERTM expressing 3T3 cells. Shown 
Development 144: doi:10.1242/dev.150656: Supplementary information
D
ev
el
o
pm
en
t •
 S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
are untreated empty vector cells (BP2 Cont.) and Control (BP2) and Sox2ERTM 
expressing cells at 24, 48 and 72h after addition of 4-OHT (10-6M). Representative 
blot shown from 3 independent experiments. 
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 Figure S7: Measurement of cell nuclei number in control and Sox2HomoOE nerves. 
Transverse sciatic nerve sections stained with Hoechst dye (Ho) to reveal GFP 
expression and numbers of nuclei from P3 control (A, B) P3 Sox2HomoOE (C, D), P7 
control (F, G) P7 Sox2HomoOE (H, I), P60 control (J, K) and Sox2HomoOE (L, M) nerves. 
Scale Bar 20m. E. Counts of nuclei per nerve section from P3 control and 
Sox2HomoOE sciatic nerves. Two sided two sample Student’s t test; n=3 for each 
mouse genotype. 
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Figure S8: Raised numbers of T-lymphocytes in intact P60 Sox2HomoOE nerves. 
Immunolabelling of P60 control (A-C) and Sox2HomoOE (D-F) nerves with CD3 
antibody to identify T-lymphocytes within the nerve. Scale bar 20m. Inset shows 
higher magnification of CD3 positive T-cells in Sox2HomoOE nerve G. Graph showing 
an increase, although not significant, in T-lymphocyte number in Sox2HomoOE nerves. 
Two sided two sample Student’s t test; n=3 for each mouse genotype. 
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Figure S9: Morphology of control and Sox2HetOE nerves following injury. A. Scatter 
plot of G-ratio versus axonal diameter in control and Sox2HetOE distal sciatic nerves at 
21 days post-crush injury. B. Graph showing measurements of axonal diameter in 
control and Sox2HetOE nerves at 21d post-crush injury. C-F. TEM images of distal 
sciatic nerve from control (C, D) and Sox2HetOE (E, F) nerves. Arrows indicate the 
increased presence of myelin ovoids (MO), macrophages (MØ) and lipid droplets 
(LD) at this timepoint in Sox2HetOE nerves (E, F). Scale bars are as shown for each 
panel. G. Graph showing counts of F4/80/Iba1 double-positive macrophage numbers 
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in intact and injured (21 days post-crush injury) control and Sox2HetOE nerves. H. 
Graph showing counts of NIMP-R14 positive neutrophils 21 days post-crush injury in 
control and Sox2HetOE nerves. B, G, H. Two sided two sample Student’s t test; n=3 
for each mouse genotype. 
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Figure S10: Regulation of Necl4 by Sox2. A-D. Necl4 immunolabelling of rat 
Schwann cells infected with GFP control (A, B) or Sox2 (C, D) expressing 
adenoviruses. Scale bar 20m. E. Western blot of nerve samples from Sox2HetOE and 
Sox2HomoOE nerves at P7 and P14 timepoints. F. Semi-quantitative PCR of Necl4 and 
Sox2 mRNA levels in rat Schwann cells infected with GFP control and Sox2 
expressing adenoviruses.  
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Supplementary Methods. 
 
Sensory Testing 
Sensory function testing was carried out on 6 week old mice and assessed using 
Von Frey Hairs and the response to toe pinching on a minimum of n=3 per genotype. 
For Von Frey filament hair testing, mice were placed into a plastic cage on a metal 
mesh floor and Von Frey filaments ranging from 0.008-10g were applied to the mid-
plantar surface of the right hindpaw (when in contact with the cage lid) for 5-8 
seconds. Filaments were applied in ascending order and the smallest filament to 
induce a foot withdrawal response was considered the threshold stimulus (Vogelaar 
et al., 2004). Three recordings were taken over three consecutive days.  
For toe pinch testing: The distal part of the lateral three toes were pinched lightly 
using a pair of forceps. Hind limb withdrawal upon pinch was taken as a positive 
response. Three measurements were taken over three consecutive days (Arthur-
Farraj et al., 2012). 
Construction of Sox2ERTM protein and retroviral infection. 
For generation of the 4-hydroxytamoxifen-regulatable Sox2-estrogen receptor fusion 
protein, (Sox2ERTM), the Sox2 cDNA was amplified by PCR using sequence specific 
primers and cloned into the pBP3:hbERTM vector (Garner et al., 2002). Inclusion of a 
BamH1 restriction enzyme site, within the primers, at the 5’ end of the cDNA and an 
EcoR1 site at the 3’ end allowed the in-frame cloning of the Sox2 cDNA with the 
estrogen receptor sequence to make the Sox2ERTM fusion protein. The correct 
sequence of the Sox2 cDNA and in-frame fusion to the estrogen receptor cDNA was 
verified by DNA sequencing. 
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Retrovirus was prepared as previously described and Swiss 3T3 fibroblasts infected 
and selected in puromycin  for experiments (Morgenstern and Land, 1991). Swiss 
3T3 cells were grown and selected in DMEM (low glucose) plus 10% donor calf 
serum containing 2.5 g/ml puromycin. For immunocytochemistry and western 
blotting experiments, as for Schwann cells, cells were transferred into defined 
medium (DM) at time zero.  4-Hydroxytamoxifen (4-OHT, 10-6M) or ethanol control 
were added at time zero and cells fixed or lysed 48 or 72 hours later. 
Culture of Schwann cells and Adenoviral infection: 
Schwann cells were prepared from the sciatic nerve and brachial plexus of post-natal 
day 3 rats as previously described (Brockes et al., 1979). Control GFP and 
GFP/Sox2 adenoviruses have been previously described (Le et al., 2005, Parrinello 
et al., 2010). For RNA work, cells were lysed 48h after infection for RNA preparation. 
Low calcium DM was prepared by substituting normal DMEM media for DMEM 
containing no calcium chloride. 
RNA preparation and semi-quantitative PCR. 
Total RNA was prepared from infected rat Schwann cells using a Qiagen RNeasy kit. 
cDNA. Total mRNA was extracted and first stand cDNA were synthesised with M-
MLV reverse transcriptase (Promega) and random hexamer primers (Promega). The 
following primers were used for RT-PCR. Sox2 (forward 5’ 
AGACGCTCATGAAGAAGGATAAG 3’; reverse 5’ 
GAGCTGGTCATGGAGTTGTACTG 3’), Necl4 (forward 5’ 
AGGGAGGGAGACACTCTGGTGCTG  3’; reverse 5’ 
GTCATAGACCACAAGCACGTAGAG 3’) and 18S rRNA (forward 5’ 
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CCTCGAAAGAGTCCTGTA 3’; reverse 5’ GGGAACGCGTGCATTTAT 3’). PCR 
products were electrophoresed on agarose gels for visualisation. 
 
DRG/Schwann cell co-cultures and electron microscopy: 
DRG were isolated from E13.5 FVB mice embryos and plated on 35 mm plastic 
dishes coated with rat collagen I (Cultrex). Five DRGs were plated in each dish in C 
medium (MEM, 2 mM L-glutamine (Gibco), 10% FBS, 4 mg/ml d-glucose (Sigma-
Aldrich), 50 ng/ml NGF (Harlan Laboratories)) supplemented with 100 U/ml penicillin 
and 100 µg/ml streptomycin (Gibco). In order to purify the neurons, on day 2 the C 
medium was replaced with NB medium (Neurobasal, 4 g/l d-glucose, 2 mM l-
glutamine, 50 ng/ml NGF and B27 (Gibco)) supplemented with 10mm 5-Fluoro-2′-
deoxyuridine (FdU) and 10mM Uridine (Sigma-Aldrich) and after two days the 
medium were replaced with NB without FdU and Uridine. The treatment was 
repeated three times in order to completely eliminate Schwann cells and fibroblasts 
from the culture. DRG neurons were then seeded with 200,000 infected or non-
infected Schwann cells per DRG. Five days after the seeding 50 mg/ml of ascorbic 
acid (AA) (Sigma-Aldrich) were added to the fresh medium to induce myelination. 
The medium + AA was replaced every two days. After 14 or 21 days of AA treatment, 
the DRG were washed with phosphate buffer, fixed in 2% glutaraldeyde for 30 
minutes at room temperature and then treated as previously described (Occhi et al., 
2005) to prepare the samples for electron microscopy analysis.  
Schwann cell culture and lentiviral transfection for SC/DRG co-cultures: 
Primary Rat Schwann cells were dissected from P3 rats and cultured as described 
(Feltri et al., 1992). Cells were transduced with lentiviruses expressing Sox2-IRES-
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GFP or IRES-GFP empty vector control. Transduction efficiency was assessed by 
counting GFP positive cells, 3 days after infection. The percentage of GFP positive 
cells was always greater than 70%. Schwann cells were then trypsinized, counted 
and seeded on purified DRG neurons. 
Immunolabelling. 
Antibodies against Necl4 were a gift from Prof. Patrice Maurel (Rutgers University, 
Newark, USA). Antibodies for the neutrophil marker NIMP-R14 were from Abcam 
(ab2557). Immunolabelling of GFP and GFP/Sox2 infected rat Schwann cells with 
antibodies against Necl4 was as described (Maurel et al., 2007). 
Scanning electron microscopy:  
Cultures of control GFP and GFP/Sox2 expressing Schwann cells were prepared for 
scanning electron microscopy as previously described  (Doddrell et al., 2013). 
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